226 related articles for article (PubMed ID: 24649232)
1. Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer.
Qiao EQ; Ji M; Wu J; Li J; Xu X; Ma R; Zhang X; He Y; Zha Q; Song X; Zhu L; Tang JH
Mol Clin Oncol; 2013 Jul; 1(4):703-710. PubMed ID: 24649232
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
3. [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and
the correlation among them].
Li X; Wang Q; Fu L; Liu M; Yu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):973-8. PubMed ID: 26408616
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use.
Chand P; Garg A; Singla V; Rani N
Niger J Surg; 2018; 24(2):100-106. PubMed ID: 30283220
[TBL] [Abstract][Full Text] [Related]
5. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
6. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
[TBL] [Abstract][Full Text] [Related]
7. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
8. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.
Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F
Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337
[TBL] [Abstract][Full Text] [Related]
11. Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical study.
Naik PS; Deshmukh S; Khandeparkar SG; Joshi A; Babanagare S; Potdar J; Risbud NS
J Midlife Health; 2015; 6(4):178-83. PubMed ID: 26903759
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
13. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
[TBL] [Abstract][Full Text] [Related]
14. Mucinous Breast Carcinoma: Clinicopathological Comparison With Invasive Ductal Carcinoma.
Hashmi AA; Zia S; Yaqeen SR; Ahmed O; Asghar IA; Islam S; Afzal A; Irfan M; Zia F; Ali J
Cureus; 2021 Mar; 13(3):e13650. PubMed ID: 33824803
[TBL] [Abstract][Full Text] [Related]
15. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.
Verma S; Bal A; Joshi K; Arora S; Singh G
APMIS; 2012 Dec; 120(12):1008-19. PubMed ID: 23030684
[TBL] [Abstract][Full Text] [Related]
18. Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer.
Shapochka DO; Zaletok SP; Gnidyuk MI
Exp Oncol; 2012 Dec; 34(4):358-63. PubMed ID: 23302996
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of WT1 expression in invasive breast carcinoma with >90% mucinous component.
Xu X; Bi R; Shui R; Yu B; Cheng Y; Tu X; Yang W
J Clin Pathol; 2022 Dec; 75(12):832-836. PubMed ID: 34244341
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
Zhu X; Ying J; Wang F; Wang J; Yang H
Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
